ウェルズ・ファーゴはRAPTセラピューティクス(RAPT.US)のレーティングを強気に据え置き、目標株価を17ドルに据え置いた
Rapt Therapeutics Is Maintained at Neutral by UBS
UBSはRAPTセラピューティクス(RAPT.US)のレーティングを中立に据え置き、目標株価を2ドルに引き下げた
H.C. WainwrightはRAPTセラピューティクス(RAPT.US)のレーティングを中立に据え置き
RAPT Therapeutics Analyst Ratings
バークレイズ銀行はRAPTセラピューティクス(RAPT.US)のレーティングを中立に引き下げ、目標株価を4ドルに引き下げた
RAPT Therapeutics Analyst Ratings
H.C. WainwrightはRAPTセラピューティクス(RAPT.US)のレーティングを中立に据え置き
RAPT Therapeutics Analyst Ratings
Barclays Downgrades RAPT Therapeutics to Equalweight, Price Target at $4
RAPT Therapeutics Analyst Ratings
RAPT Therapeutics Analyst Ratings
RAPT Therapeutics Analyst Ratings
UBS Downgrades RAPT Therapeutics to Neutral, Lowers Price Target to $10
RAPT Therapeutics Analyst Ratings
JPMorgan Downgrades RAPT Therapeutics to Neutral From Overweight, Price Target Is $15
RAPT Therapeutics Analyst Ratings
RAPT Therapeutics Analyst Ratings
Wolfe Research Initiates Coverage On RAPT Therapeutics With Outperform Rating, Announces Price Target of $39
RAPT Therapeutics Analyst Ratings